Balance Sheet
Liabilities and Shareholders Equity
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Accounts Payables (2017 - 2024)

KalVista Pharmaceuticals' Accounts Payables history spans 10 years, with the latest figure at $5.7 million for Q4 2024.

  • For Q4 2024, Accounts Payables changed N/A year-over-year to $5.7 million; the TTM value through Dec 2024 reached $5.7 million, changed N/A, while the annual FY2024 figure was $9.1 million, N/A changed from the prior year.
  • Accounts Payables for Q4 2024 was $5.7 million at KalVista Pharmaceuticals, up from $5.2 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $10.8 million in Q3 2024 and bottomed at $641000.0 in Q1 2021.
  • The 4-year median for Accounts Payables is $4.0 million (2023), against an average of $4.4 million.
  • The largest annual shift saw Accounts Payables tumbled 78.28% in 2021 before it skyrocketed 113.28% in 2024.
  • A 4-year view of Accounts Payables shows it stood at $2.2 million in 2020, then plummeted by 70.5% to $641000.0 in 2021, then surged by 663.81% to $4.9 million in 2023, then increased by 16.95% to $5.7 million in 2024.
  • Per Business Quant, the three most recent readings for KALV's Accounts Payables are $5.7 million (Q4 2024), $5.2 million (Q4 2024), and $10.8 million (Q3 2024).